ATRA · Atara Biotherapeutics, Inc. · Documents
$9.16
+0.20 (+2.23%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$93.25M
Shares
10.04M
Volume · Oct 20
14.85K
Avg daily vol (3M)
45.84K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | — | 2021-08-10 | 2021-08-09 | |
| 8-K | — | 2021-08-09 | — | |
| 10-Q | — | 2021-08-09 | 2021-06-30 | |
| 8-K | — | 2021-06-09 | 2021-06-08 | |
| 8-K | — | 2021-05-04 | — | |
| 10-Q | — | 2021-05-04 | 2021-03-31 | |
| DEF 14A | — | 2021-04-22 | 2021-06-08 | |
| 10-K | — | 2021-03-01 | 2020-12-31 | |
| 8-K | — | 2021-03-01 | — | |
| 8-K | — | 2021-01-11 | — | |
| 8-K | — | 2021-01-04 | — | |
| 8-K | — | 2020-12-09 | 2020-12-08 | |
| 8-K | — | 2020-12-07 | 2020-12-04 | |
| 10-Q | — | 2020-11-09 | 2020-09-30 | |
| 8-K | — | 2020-11-09 | — | |
| 10-Q | — | 2020-08-05 | 2020-06-30 | |
| 8-K | — | 2020-08-05 | — | |
| 8-K | — | 2020-06-19 | 2020-06-16 | |
| 8-K | — | 2020-05-28 | 2020-05-26 | |
| 8-K | — | 2020-05-12 | 2020-05-08 | |
| 8-K | — | 2020-05-06 | — | |
| 10-Q | — | 2020-05-06 | 2020-03-31 | |
| 8-K | — | 2020-04-30 | 2020-04-29 | |
| DEF 14A | — | 2020-04-22 | 2020-06-16 | |
| 10-K | — | 2020-02-27 | 2019-12-31 | |
| 8-K | — | 2020-02-27 | — |
Showing 101–126 of 126 filings